HER-2/neu Expression as a Predictive Factor for Response to Anthracycline-Based Chemotherapy in a Mexican Population of Locally Advanced Breast Cancer Patients

Abstract

Breast cancer is the second most frequent tumor in Mexico 30-50% are diagnosed in locally advanced stages requiring neoadjuvant chemotherapy. The overexpression of HER-2/neu has been identified as a chemotherapy response predictor. The objective of our study was to identify response predictive factors to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer. Data were collected from clinical records of patients with neoadjuvant anthracycline-based chemotherapy, for clinical stage III breast cancer from 1992 to 1997. Paraffin blocks were reviewed to determine histologic grade, HER-2/neu expression, and ploidy. Patients were divided in two groups: A, 56 cases responding to chemotherapy and, B, 20 nonresponders. Mean age was 50.1 and 45.4 for groups A and B, respectively (OR 7.02, p = 0.004), and those premenopausal were 43% and 70%, respectively (OR 3.1, p = 0.04). Mean tumor size was 5 cm in responders and 8 cm for nonresponders (OR 4, p = 0.02). Clinical stage III-B 16% and 70% for groups A and B (OR 12.2, p = 0.000); tumors were aneuploid in 39% of responders and 18.7% for nonresponders. HER-2 /neu was overexpressed in 64.2% and 50% for groups A and B (OR 3.6, p = 0.06). On multivariate analysis significance was conserved only for age, clinical stage, and size. HER-2/neu lost significance. Age and size were importantly related to tumor response, a higher percentage of HER-2/neu overexpression was observed in responders, without significance due to small sample size. It would be important to study a larger number of patients to obtain more conclusive results.

MRI radiogenomics for intelligent diagnosis of breast tumors and accurate prediction of neoadjuvant chemotherapy responses-a review

“…Currently, genomics research focuses on predicting the efficacy of NAC by detecting the correlation between tumor tissue gene expression and NAC efficacy. By detecting the gene expression of needle puncture tissue samples in patients before NAC, the expression of multiple genes including ER, PgR, pS2, HER2 / neu, BRCA-1, Bcl-2, P53, P21, Ki-67, and TopoⅡ, can be correlated to the efficacy of NAC [22][23][24][25][26][27][28]. Two companies, Oncotype DX and Mamma Print have constructed a multi-gene expression profile for predicting the efficacy of NAC.…”

Chimiothérapie néoadjuvante par anthracyclines dans le cancer du sein : facteurs prédictifs de réponse

“…Les ré sultats des é tudes sont variables, Munoz Gonzalez et al [14] retrouvent qu'un âge jeune (< 45 ans) est pré dictif d'une mauvaise ré ponse, tandis que Dieras et al [8] rapportent un taux de pCR plus important pour les patientes plus jeunes (< 50 ans), mais l'âge ne semble pas être dé terminant dans d'autres sé ries [15,16].…”

“…Une taille tumorale clinique infé rieure à 4 cm est pré dictive d'une bonne ré ponse avec un taux plus important de pCR dans la majorité des é tudes [4,11,14,15,[17][18][19], ceci est en accord avec nos ré sultats.…”

Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates

“…A reduced expression of BRCA1 has been associated with increased invasiveness of sporadic or inherited BC [9]; and as is the case for other gene expression markers [10][11][12][13], BRCA1 expression influences the response of BC to chemotherapeutic agents [14,15], which might in the future have an impact on treatment choices [16]. Thus, there is increasing interest in BRCA1 and BRCA2 expression as alternative biologic markers of cancer behavior and response to treatment [7,[16][17][18].…”